adagrasib
mirati
['sclc', 'adagrasib', 'nsclc']
adagrasib, an investigational krasg12c inhibitor drug, has shown durable clinical benefit in patients with previously treated, advanced krasg12c-mutated nsclc. #asco22 
MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.